Abstract 476P
Background
Androgen receptor (AR) is a steroid receptor gene located on X chromosome at Xq11–12 and is overexpressed in several solid tumors representing a potential therapeutic target. AR activity and expression is mediated by several genes located on the X chromosome such as: FLNA, UXT and the MAGE family genes (MAGEA1, MAGEA2, MAGEA3, MAGEA9, MAGEA11, MAGEC1, MAGEC2). In this study we investigated the role of AR expression and regulation in patients with gliomas.
Methods
Adult patients with pathologically confirmed grade 2 or 3 or 4 adult-type diffuse gliomas (according to the WHO 2021 classification) treated in our Institution have been evaluated. The AR expression and regulatory status was investigated by Immunohistochemistry (ICH) and gene methylation analysis.
Results
Overall, samples from 50 adult patients have been evaluated. 26 patients were males and 24 were females, with a median age of 51.9 years (range 26.3-76.9). The AR expression detected by ICH was predominant in males (p=0.04), in glioblastoma (GBM) patients IDH-wild type (compared to lower grade adult-type diffuse gliomas, p=0.04), and in astrocytoma (compared to oligodendrogliomas IDH-mutant and 1p19q codeleted, p=0.02). There was an association between AR expression and MGMT methylation, being AR expression more frequently detected in MGMT unmethylated gliomas (p=0.02). AR was found hypomethylated in cases with immunohistochemical positivity AR (Kruskal Wallis < 0.05). UXT, MAGEA1, and MAGEA1-11 were hypermethylated in AR-positive gliomas (Kruskal Wallis < 0.05). AR hypomethylation was deeper in GBM (Kruskal Wallis <0.05).
Conclusions
AR expression is higher in MGMT unmethylated tumors, astrocytoma, glioblastoma IDH-WT, and male patients. The methylation of AR regulatory genes on the X chromosome mediates AR expression. These data indicate that the AR pathway could be important in adult-type diffuse gliomas suggesting a potential role of antiandrogen therapies in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Istituto delle Scienze Neurologiche di Bologna.
Funding
CARISBO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
489P - Interfering with the tumor microenvironment of glioblastoma: An in vitro study
Presenter: Serena Mastantuono
Session: Poster session 16
490P - Inhibiting glioma cells' migration: Exploring Rho-GTPases as a potential therapeutic target
Presenter: Irene Giulia Rolle
Session: Poster session 16
Resources:
Abstract
491P - SRSF7 promotes glioblastoma progression via CDK1-mediated G2/M phase arrest of GBM cells
Presenter: Ya qin Hu
Session: Poster session 16
Resources:
Abstract
492P - Linking cellular drug responses to corresponding metabolomic tissue signatures in gliomas
Presenter: Stefanie Stanzer
Session: Poster session 16
493P - The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
Presenter: Kreina Vega Cano
Session: Poster session 16
494P - Effect of a new method for operating electric field patches on scalp reactions in glioblastoma patients receiving tumor treating fields
Presenter: Jinghui Liu
Session: Poster session 16
Resources:
Abstract
495P - Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: A single-center retrospective analysis of 118 cases
Presenter: Feng Chen
Session: Poster session 16
496P - Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients
Presenter: Ariane Steindl
Session: Poster session 16
497P - Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
Presenter: Junmin Song
Session: Poster session 16